The clinical development path is rife with complexity that can stall
or stop a drug’s journey to market. Paul Evans, Jeetendra Rao and
Abigaile Betteridge at PAREXEL International explain that, while
there is no single transformative solution to streamline clinical
development, biopharmaceutical companies can take common
sense steps to mitigate risks, control costs, improve efficiency, and
gain competitive advantage.